This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Diagnostic accuracy of the Panbio COVID-19 Antigen rapid test device for SARS-CoV-2 detection in Kenya, 2021: A field evaluation
Preprint
in English
| medRxiv
| ID: ppmedrxiv-22275439
ABSTRACT
BackgroundAccurate and timely diagnosis is essential in limiting the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Real-time reverse transcription-polymerase chain reaction (rRT-PCR), the reference standard, requires specialized laboratories, costly reagents, and a long turnaround time. Antigen rapid diagnostic tests (Ag RDTs) provide a feasible alternative to rRT-PCR since they are quick, relatively inexpensive, and do not require a laboratory. The WHO requires that Ag RDTs have a sensitivity [≥]80% and specificity [≥]97%. MethodsThis evaluation was conducted at 11 health facilities in Kenya between March and July 2021. We enrolled persons of any age with respiratory symptoms and asymptomatic contacts of confirmed COVID-19 cases. We collected demographic and clinical information and two nasopharyngeal specimens from each participant for Ag RDT testing and rRT-PCR. We calculated the diagnostic performance of the Panbio Ag RDT against the US Centers for Disease Control and Preventions (CDC) rRT-PCR test. ResultsWe evaluated the Ag RDT in 2,245 individuals where 551 (24.5%, 95% CI 22.8-26.3%) tested positive by rRT-PCR. Overall sensitivity of the Ag RDT was 46.6% (95% CI 42.4-50.9%), specificity 98.5% (95% CI 97.8-99.0%), PPV 90.8% (95% CI 86.8-93.9%) and NPV 85.0% (95% CI 83.4-86.6%). Among symptomatic individuals, sensitivity was 60.6% (95% CI 54.3-66.7%) and specificity was 98.1% (95% CI 96.7-99.0%). Among asymptomatic individuals, sensitivity was 34.7% (95% CI 29.3-40.4%) and specificity was 98.7% (95% CI 97.8-99.3%). In persons with onset of symptoms <5 days (594/876, 67.8%), sensitivity was 67.1% (95% CI 59.2-74.3%), and 53.3% (95% CI 40.0-66.3%) among those with onset of symptoms >7 days (157/876, 17.9%). The highest sensitivity was 87.0% (95% CI 80.9-91.8%) in symptomatic individuals with cycle threshold (Ct) values [≤]30. ConclusionThe overall sensitivity and NPV of the Panbio Ag RDT were much lower than expected. The specificity of the Ag RDT was high and satisfactory; therefore, a positive result may not require confirmation by rRT-PCR. The kit may be useful as a rapid screening tool for only symptomatic patients in high-risk settings with limited access to RT-PCR. A negative result should be interpreted based on clinical and epidemiological information and may require retesting by rRT-PCR.
Full text:
Available
Collection:
Preprints
Database:
medRxiv
Type of study:
Diagnostic study
/
Experimental_studies
/
Observational study
/
Prognostic study
Language:
English
Year:
2022
Document type:
Preprint